1058
document
Effect of granulocyte/colony-stimulating factor on the onset of the adult respiratory distress syndrome . To evaluate the effect of granulocyte/colony-stimulating factor ( G-CSF ) on the onset of the adult respiratory distress syndrome ( ARDS ) , we investigated whether the incidence of ARDS due to pulmonary infection differed between the G-CSF group which received chemotherapy with G-CSF and historical controls without G-CSF . We evaluated 132 patients with hematological malignancy in complete remission without any main organ dysfunction who had been treated between April 1983 and December 1997 . We compared the incidence of ARDS due to pulmonary infection between those who received G-CSF and those who did not . There was no remarkable difference in the number of patients , gender , age , or distribution of primary diseases between the two groups . The intensity of chemotherapy was not considered to significantly differ between the two groups , though the chemotherapy regimens administered differed slightly . In the G-CSF group , the duration of neutropenia was significantly shorter and the frequency of documented infection was significantly decreased . We could not find any relationship between ARDS due to pulmonary infection and any anticancer agent or antibiotics . There was no relationship between the kind of G-CSF and the incidence of ARDS due to pulmonary infection ( per chemotherapy session ; p > 0.10 , per case ; p > 0.30 , chi2 test ) . The incidence of ARDS due to pulmonary infection per chemotherapy session was 4.21 % , and showed a higher tendency in the G-CSF group ( p < 0.100 , chi2 test ) . The incidence of ARDS due to pulmonary infection per case was 25.4 % and was significantly higher in the G-CSF group ( p < 0.025 , chi2 test ) . The incidence of ARDS due to pulmonary infection was higher in the G-CSF group than in the controls , suggesting that G-CSF promotes the development of ARDS due to pulmonary infection .
1059
Intervention_Physical
granulocyte/colony-stimulating factor
1060
Intervention_Physical
granulocyte/colony-stimulating factor ( G-CSF )
1061
Intervention_Physical
chemotherapy with G-CSF
1062
Intervention_Physical
historical controls without G-CSF
1063
Intervention_Physical
G-CSF
1064
Intervention_Physical
G-CSF
1065
Intervention_Physical
G-CSF
1066
Intervention_Pharmacological
G-CSF
1067
Intervention_Pharmacological
G-CSF
1068
Intervention_Pharmacological
G-CSF
1069
Intervention_Pharmacological
G-CSF
1070
Outcome_Other
intensity of chemotherapy
1071
Outcome_Physical
duration of neutropenia
1072
Outcome_Physical
pulmonary infection
1073
Outcome_Physical
pulmonary infection
1074
Outcome_Physical
incidence of ARDS due to pulmonary infection per chemotherapy session
1075
Outcome_Physical
incidence of ARDS due to pulmonary infection was higher in the G-CSF group
1076
Participant_Condition
respiratory distress syndrome
1077
Participant_Condition
G-CSF group which received chemotherapy with G-CSF
1078
Participant_Condition
historical controls without G-CSF
1079
Participant_Sample-size
132
1080
Participant_Condition
patients with hematological malignancy in complete remission without any main organ dysfunction who had been treated between April 1983 and December 1997 .
1081
Participant_Condition
no remarkable difference in the number of patients , gender , age , or distribution of primary diseases between the two groups